Aminoglycosides: old friend... new foe?

N.J. Simmonds, A.H. Thomson

Research output: Contribution to journalEditorial

Abstract

Over a relatively short period, cystic fibrosis (CF) has gone from a disease of dying children to one where survival well into adulthood is expected. It was recently reported that by 2025, the adult CF population in Western Europe would increase by 75% [1]. Although the reasons for improved survival are complex, one contributor is the aggressive use of antibiotics including aminoglycosides. However, aminoglycosides have well-recognised adverse effects, particularly nephrotoxicity and ototoxicity. Clear relationships between these effects and aminoglycoside concentrations or exposure have yet to be defined.
LanguageEnglish
Pages411-412
Number of pages2
JournalJournal of Cystic Fibrosis
Volume15
Issue number4
Early online date2 Jun 2016
DOIs
Publication statusPublished - 1 Jul 2016

Fingerprint

Aminoglycosides
Cystic Fibrosis
Survival
Anti-Bacterial Agents
Population

Keywords

  • cystic fibrosis
  • tobramycin
  • aminoglycoside

Cite this

Simmonds, N.J. ; Thomson, A.H. / Aminoglycosides : old friend... new foe?. In: Journal of Cystic Fibrosis. 2016 ; Vol. 15, No. 4. pp. 411-412.
@article{c2ac844eecc344e9aea819679773c2cc,
title = "Aminoglycosides: old friend... new foe?",
abstract = "Over a relatively short period, cystic fibrosis (CF) has gone from a disease of dying children to one where survival well into adulthood is expected. It was recently reported that by 2025, the adult CF population in Western Europe would increase by 75{\%} [1]. Although the reasons for improved survival are complex, one contributor is the aggressive use of antibiotics including aminoglycosides. However, aminoglycosides have well-recognised adverse effects, particularly nephrotoxicity and ototoxicity. Clear relationships between these effects and aminoglycoside concentrations or exposure have yet to be defined.",
keywords = "cystic fibrosis, tobramycin, aminoglycoside",
author = "N.J. Simmonds and A.H. Thomson",
year = "2016",
month = "7",
day = "1",
doi = "10.1016/j.jcf.2016.05.011",
language = "English",
volume = "15",
pages = "411--412",
journal = "Journal of Cystic Fibrosis",
issn = "1569-1993",
number = "4",

}

Aminoglycosides : old friend... new foe? / Simmonds, N.J.; Thomson, A.H.

In: Journal of Cystic Fibrosis, Vol. 15, No. 4, 01.07.2016, p. 411-412.

Research output: Contribution to journalEditorial

TY - JOUR

T1 - Aminoglycosides

T2 - Journal of Cystic Fibrosis

AU - Simmonds, N.J.

AU - Thomson, A.H.

PY - 2016/7/1

Y1 - 2016/7/1

N2 - Over a relatively short period, cystic fibrosis (CF) has gone from a disease of dying children to one where survival well into adulthood is expected. It was recently reported that by 2025, the adult CF population in Western Europe would increase by 75% [1]. Although the reasons for improved survival are complex, one contributor is the aggressive use of antibiotics including aminoglycosides. However, aminoglycosides have well-recognised adverse effects, particularly nephrotoxicity and ototoxicity. Clear relationships between these effects and aminoglycoside concentrations or exposure have yet to be defined.

AB - Over a relatively short period, cystic fibrosis (CF) has gone from a disease of dying children to one where survival well into adulthood is expected. It was recently reported that by 2025, the adult CF population in Western Europe would increase by 75% [1]. Although the reasons for improved survival are complex, one contributor is the aggressive use of antibiotics including aminoglycosides. However, aminoglycosides have well-recognised adverse effects, particularly nephrotoxicity and ototoxicity. Clear relationships between these effects and aminoglycoside concentrations or exposure have yet to be defined.

KW - cystic fibrosis

KW - tobramycin

KW - aminoglycoside

U2 - 10.1016/j.jcf.2016.05.011

DO - 10.1016/j.jcf.2016.05.011

M3 - Editorial

VL - 15

SP - 411

EP - 412

JO - Journal of Cystic Fibrosis

JF - Journal of Cystic Fibrosis

SN - 1569-1993

IS - 4

ER -